"There is a palpable need for business to explore the issues Dhanda raises. Guiding Icarus offers a flight plan."
-from the Foreword by Philip R. Reilly
Merging Bioethics with Corporate Interests
Rahul K. Dhanda
While bioethicists may enjoy the most thorough appreciation of both the promise and perils of new biotechnologies, international corporations are in fact the entities generating these technologies and determining their application. An industry insider versed in the language of bioethics, Rahul Dhanda offers in Guiding Icarus: Merging Bioethics with Corporate Interests a Rosetta stone to these two camps, explaining why each needs the other, why their disparate concerns often cohere, and why an ethical business is likely a successful one.
The author develops a dialogue between bioethics and corporate interests by examining case studies of several hot-button issues, including:
* Genetically modified foods
* DNA data banking
* Personalized medicine
* Stem cell research
In each instance he provides a treatment of the particular science under consideration, a list of the benefits of the technology, a description of the ethical issues involved, an account of past industry response, and recommendations for future action. Given the expansive nature of biotechnology, ramifications in the pharmaceutical and agricultural industries are covered in depth as well. The book also features a Foreword by world-renowned bioethicist and biotechnology CEO Philip R. Reilly as well as a step-by-step discussion of the components of business and bioethical issues.
Written for a general audience, Guiding Icarus will be particularly useful to biotechnologists, regulatory affairs managers, and corporate officers of biotechnology firms, as well as bioethicists in the academic community. Dhanda's peerless text provides a unique tool for understanding and addressing the ethical dilemmas confronting society in the 21st century.
Table of contents
Genetically Modified Foods.
DNA Data Banking.
"...particularly useful to corporate biotech managers due to Dhanda's explanation of the issues and suggestions on how to engage the public...inherent value in this discourse is how Dhanda explains how an ethical biotech business is likely to be a successful one." (Genomics & Proteomics, May 2002)
"useful to biotechnologists, regulatory affairs managers, and corporate officers of biotech firms, as well as bioethicists..." (Genetic Engineering News, July 2002)
"...if you read The Economist you'll doubtless find this of interest..." (Focus, August 2002)
"...offers an insider's view on why a bridge is needed to merge bioethics with corporate needs...written for the general audience...is especially useful to biotechnologists, regulatory affairs managers, and corporate officers of biotech firms, as well as bioethicists..." (Genetic Engineering News, Vol. 22, No. 13, July 2002)
"...lays out a blueprint for executives...focusing on four subjects..." (HBS (Harvard Business School) Working Knowledge, July 2002)
"This book should stimulate much useful discussion in the biotechnology industry...the author should be congratulated." (Nature Biotechnology, August 1, 2002)